UC Davis researchers seek to develop a non-addictive, monthly painkiller.
During the pandemic, doctors employed infusions of monoclonal antibodies (lab-made antibodies) to help patients fight COVID-19 infections. University of California, Davis researchers are now attempting to develop monoclonal antibodies that may aid in the treatment of chronic pain. The objective is to create a monthly non-addictive pain medication that can be used instead of opioids.
The project is led by Vladimir Yarov-Yarovoy and James Trimmer, professors in the Department of Physiology and Membrane Biology at the UC Davis School of Medicine. They’ve established an interdisciplinary team that includes several of the same experts that are working on turning tarantula venom into a pain medication.
Yarov-Yarovoy and Trimmer were awarded a $1.5 million grant earlier this year by the National Institutes of Health’s HEAL Initiative, a determined effort to hasten the development of scientific solutions to the country’s opioid crisis.
People can become addicted to opioids due to chronic pain. According to the CDC National Center for Health Statistics, there will likely be 107,622 drug overdose deaths in the US in 2021, up from an expected 93,655 deaths in 2020.
“Recent breakthroughs in structural and computational biology — using computers to understand and model biological systems — have set the stage for applying new approaches to create antibodies as superior therapeutic candidates to treat chronic pain,” said Yarov-Yarovoy, the principal investigator for the award.
“Monoclonal antibodies are the fastest growing sector of the pharmaceutical industry and have many advantages over classical small molecule drugs,” Trimmer said. Small molecule drugs are drugs that can easily enter cells. They are widely used in medicine.
Trimmer’s lab has created thousands of different monoclonal antibodies for various purposes over many years, but this is the first attempt to generate antibodies aimed at pain relief.
Monoclonal antibodies are already being used for migraine
Although it may seem very futuristic, the Food and Drug Administration has already approved monoclonal antibodies to treat and prevent migraine. These new medications act on a migraine-associated protein called calcitonin gene-related peptide.
The project at UC Davis has a different target—specific ion channels in nerve cells known as voltage-gated sodium channels. The channels are like “pores” on the nerve cell.
“Nerve cells are responsible for transmitting pain signals in the body. Voltage-gated sodium ion channels in nerve cells are the key transmitters of pain,” explained Yarov-Yarovoy. “We aim to create antibodies that will bind to these specific transmission sites at the molecular level, inhibiting their activity and stopping the transmission of pain signals.”
The researchers are focused on three specific sodium ion channels associated with pain: NaV1.7, NaV1.8 and NaV1.9.
Their goal is to create antibodies that can fit into each of these channels like a key into a lock. This targeted approach is intended to stop the channels from sending pain signals but not interfere with other signals sent through the nerve cells.
The challenge is that the structures of the three channels they are attempting to block are incredibly complex.
Software programs help create virtual models
To address this, they are turning to software programs called Rosetta and AlphaFold. With Rosetta, the researchers are designing complex virtual models of proteins and analyzing which ones might best fit the NaV1.7, NaV1.8, and NaV1.9 nerve channels. With AlphaFold, the researchers independently validate proteins designed by Rosetta.
Once they identify several promising proteins, they will create antibodies that can then be tested on lab-created neural tissue. Human testing would be years away.
But the researchers are excited by the potential of this new approach. Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and acetaminophen must be taken several times per day to relieve pain. Opioid pain medications are often taken daily and run the risk of addiction.
Monoclonal antibodies, however, can circulate in the bloodstream for more than a month before they are eventually broken down by the body. The researchers anticipate that the patient would self-inject the monoclonal antibody pain medication once a month.
“For patients with chronic pain, that’s exactly what you need,” Yarov-Yarovoy said. “They experience pain, not for days, but weeks and months. The expectation is that the circulating antibodies will be able to provide sustained pain relief for weeks.”
The study was funded by the National Institutes of Health.
News
Scientists Uncover Unexpected Hidden Dangers of a Common Antibiotic
In emergency rooms and intensive care units nationwide, healthcare professionals must quickly decide on antibiotics for patients suspected of having severe infections. A recent study from the University of Michigan indicates that these rapid decisions could [...]
New research to make digital transactions quantum safe and 20 times faster
A team of experts, including Monash University researchers, has developed a new technique to implement quantum-safe digital signatures twenty times faster, resulting in speedier and safer online transactions than ever before. The research, published recently [...]
Scientists use generative AI to answer complex questions in physics
When water freezes, it transitions from a liquid phase to a solid phase, resulting in a drastic change in properties like density and volume. Phase transitions in water are so common most of us [...]
An easy pill to swallow—new 3D printing research paves way for personalized medication
A new technique for 3D printing medication has enabled the printing of multiple drugs in a single tablet, paving the way for personalized pills that can deliver timed doses. Researchers from the University of [...]
Revolutionary “Quartet Nanocage” Vaccine Effective Against Coronaviruses That Haven’t Even Emerged Yet
Researchers have created a new vaccine technology that, in tests with mice, has demonstrated protection against a wide variety of coronaviruses, including those that could cause future disease outbreaks—even those not yet identified. This [...]
Researchers Warn: AI Systems Have Already Learned How To Deceive Humans
Numerous artificial intelligence (AI) systems, even those designed to be helpful and truthful, have already learned how to deceive humans. In a review article recently published in the journal Patterns, researchers highlight the dangers of [...]
MIT’s New MRI Technique Reveals Hidden Light Deep in the Brain
A novel MRI technique developed at MIT allows for detailed imaging of bioluminescence deep within the brain, offering new insights into how brain cells develop and communicate with each other. Scientists often label cells with proteins [...]
Revolutionary mRNA Cancer Vaccine Shows Immense Promise in First-Ever Human Clinical Trial
In a first-ever human clinical trial of four adult patients, an mRNA cancer vaccine created at the University of Florida rapidly reprogrammed the immune system to target glioblastoma, the deadliest and most aggressive form of brain [...]
Human brain map contains never-before-seen details of structure
A cubic millimeter of brain tissue may not sound like much. But considering that tiny square contains 57,000 cells, 230 millimeters of blood vessels, and 150 million synapses, all amounting to 1,400 terabytes of [...]
AI Ethics Surpass Human Judgment in New Moral Turing Test
AI’s ability to address moral questions is improving, which prompts further considerations for the future. A recent study revealed that when individuals are given two solutions to a moral dilemma, the majority tend to [...]
AstraZeneca removes its Covid vaccine worldwide after rare side effect
AstraZeneca withdraws COVID-19 vaccine: The pharmaceutical giant AstraZeneca's COVID-19 vaccine is being withdrawn worldwide after the company acknowledged for the first time in court documents that it can cause a rare and dangerous side [...]
AI Transforms Drug Discovery With Faster, Safer Cancer Treatments
The new platform helped UC San Diego scientists synthesize 32 potential multi-target cancer drugs. Scientists at UC San Diego have developed a machine learning algorithm to simulate the time-consuming chemistry involved in the earliest phases of [...]
Nanotech opens door to future of insulin medication
An international team, led by researchers from Australia, have developed a system using nanotechnology that could allow people with diabetes to take oral insulin in the future. The researchers say the new insulin could [...]
COVID-19’s Impact on Child Development More Subtle Than Expected
Researchers at Johns Hopkins Children’s Center express that the study results offer a sense of reassurance, instilling “guarded optimism” regarding the developmental outcomes of young children who have been exposed to restrictions stemming from [...]
New Hope for Neurological Disorders: Scientists Have Discovered How an Essential Nutrient Enters the Brain
Researchers have discovered the process by which dietary choline crosses the blood-brain barrier. This breakthrough has potential applications in enhancing drug delivery to the brain for treating neurological disorders. A researcher from the University of [...]
Developing a tech platform for fast, robust series production of nanoparticles
Nucleic acid-based medications such as mRNA vaccines offer tremendous potential for medicine and are opening up new therapeutic approaches. These active ingredients must be enclosed inside nanoparticles to ensure that they get to where [...]